Bevacizumab after eye surgery for diabetic retinopathy
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether giving bevacizumab (a medicine that slows abnormal blood vessel growth) right after vitrectomy (a surgery to remove blood or scar tissue from the eye) can help people with advanced diabetic eye disease. The goal is to improve vision and reduce the need for more treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 1 or type 2 diabetes with active diabetic eye disease in the study eye.
- Your vision in the study eye is between 20/40 and hand motions on an eye chart.
- You need vitrectomy because of blood in the eye that hasn't cleared, scar tissue pulling on the retina, or abnormal blood vessel growth that threatens your central vision.
- You have not had a vitrectomy in the study eye before.
- Only one eye per patient can be in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This study looks at how well surgery called vitrectomy works for people with severe nonproliferative diabetic retinopathy (NPDR), a condition where high blood sugar damages the retina. The trial aims to see if this surgery can improve vision and outcomes.
This trial compares two treatments for early diabetic retinopathy—a condition where high blood sugar damages blood vessels in the eye. Researchers want to see if removing fluid from inside the eye (vitrectomy) works better than laser treatment to prevent vision loss.
This trial is testing a new laser treatment pattern for people with diabetic eye disease (proliferative diabetic retinopathy) to see if it works better than the standard approach. If you have this condition and want a less invasive treatment option, this study might be a good fit.
This study compares two ways of giving the medicine bevacizumab in the eye: into the front part (intracameral) versus deeper inside (intravitreal). It aims to see which approach better controls neovascular glaucoma and helps vision, especially when surgery (trabeculectomy) is needed.
This trial compares two standard anti-VEGF injections (aflibercept and bevacizumab) for people with diabetic macular edema who have not recently had this treatment. The goal is to see which drug works better over three monthly doses to improve vision and reduce retinal swelling.
Hear when a new Proliferative Diabetic Retinopathy - High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.